Hangzhou Alltest Biotech Co., Ltd. (SHA:688606)

Market Cap	5.00B
Revenue (ttm)	875.14M
Net Income (ttm)	318.90M
Shares Out	77.87M
EPS (ttm)	4.03
PE Ratio	15.90
Forward PE	n/a
Dividend	3.00 (4.72%)
Ex-Dividend Date	Jun 11, 2025

Volume	339,549
Average Volume	1,057,215
Open	63.55
Previous Close	63.55
Day's Range	63.02 - 64.50
52-Week Range	45.17 - 84.72
Beta	0.43
RSI	45.98
Earnings Date	Aug 29, 2025

About Hangzhou Alltest Biotech

Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. The company offers rapid diagnostic reagents, including drug and drug abuse, infectious disease, women's health, tumor marker, and cardiac marker testing products. Its products include COVID-19 antigen and antibody tests; veterinary tests; fluorescence immunoassay tests and analyzers; urine analysis solutions, biochemistry reagents, VTM, blood glucose monitoring systems, and HB hemoglobin te...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2009
• Employees: 969
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688606

Financial Performance

In 2024, Hangzhou Alltest Biotech's revenue was 866.58 million, an increase of 14.83% compared to the previous year's 754.70 million. Earnings were 302.47 million, an increase of 67.50%.